beta-lapachone has been researched along with Pancreatic Neoplasms in 10 studies
beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase
beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities.
Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In previously established pancreatic cancer xenografts in mice, β- lapachone inhibited the tumor growth when given orally rather than when combined with cyclodextrin to improve its bioavailability." | 1.72 | β-lapachone: A Promising Anticancer Agent with a Unique NQO1 Specific Apoptosis in Pancreatic Cancer. ( Iqbal, MS; Khan, R; Qadir, MI, 2022) |
| "4) or in 1 M sodium salicylate, which agrees with the desired dosing sequence of the two drugs to exert synergistic pharmacologic effect at different cell checkpoints." | 1.42 | β-Lapachone and Paclitaxel Combination Micelles with Improved Drug Encapsulation and Therapeutic Synergy as Novel Nanotherapeutics for NQO1-Targeted Cancer Therapy. ( Chen, Z; Gao, J; Liu, C; Qian, F; Yang, K; Zhang, L, 2015) |
| "Pancreatic cancer is the fourth leading cause of cancer-related deaths, in which the 5-year survival rate is less than 5%." | 1.37 | Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy. ( Barnett, CC; Bey, EA; Boothman, DA; Bornmann, WG; Brekken, RA; Dong, Y; Gao, J; Li, LS; Meng, J; Patra, B; Xie, XJ; Yan, J, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zheng, Y | 1 |
| Zhang, H | 1 |
| Guo, Y | 1 |
| Chen, Y | 1 |
| Chen, H | 1 |
| Liu, Y | 2 |
| Qadir, MI | 1 |
| Iqbal, MS | 1 |
| Khan, R | 1 |
| Beg, MS | 1 |
| Huang, X | 2 |
| Silvers, MA | 3 |
| Gerber, DE | 3 |
| Bolluyt, J | 1 |
| Sarode, V | 3 |
| Fattah, F | 2 |
| Deberardinis, RJ | 3 |
| Merritt, ME | 1 |
| Xie, XJ | 3 |
| Leff, R | 1 |
| Laheru, D | 1 |
| Boothman, DA | 6 |
| Moore, Z | 1 |
| Chakrabarti, G | 3 |
| Luo, X | 2 |
| Ali, A | 1 |
| Hu, Z | 1 |
| Fattah, FJ | 1 |
| Vemireddy, R | 1 |
| Brekken, RA | 2 |
| Breton, CS | 1 |
| Aubry, D | 1 |
| Ginet, V | 1 |
| Puyal, J | 1 |
| Heulot, M | 1 |
| Widmann, C | 1 |
| Duchosal, MA | 1 |
| Nahimana, A | 1 |
| Zhang, L | 1 |
| Chen, Z | 1 |
| Yang, K | 1 |
| Liu, C | 1 |
| Gao, J | 4 |
| Qian, F | 1 |
| Ilcheva, M | 1 |
| Moore, ZR | 2 |
| Anderson, G | 1 |
| Liu, L | 1 |
| Burma, S | 1 |
| Gerson, SL | 1 |
| Motea, EA | 1 |
| Yao, J | 1 |
| Dong, Y | 2 |
| Kilgore, JA | 1 |
| Patidar, PL | 1 |
| Cholka, A | 1 |
| Cha, Y | 1 |
| Anderson, GG | 1 |
| Kusko, R | 1 |
| Peyton, M | 1 |
| Yan, J | 2 |
| Williams, NS | 1 |
| Minna, JD | 1 |
| Beg, M | 1 |
| Bey, EA | 3 |
| Li, LS | 1 |
| Meng, J | 1 |
| Patra, B | 1 |
| Barnett, CC | 1 |
| Bornmann, WG | 1 |
| Ough, M | 1 |
| Lewis, A | 1 |
| Ritchie, JM | 1 |
| Bornmann, W | 1 |
| Oberley, LW | 1 |
| Cullen, JJ | 1 |
10 other studies available for beta-lapachone and Pancreatic Neoplasms
| Article | Year |
|---|---|
X-ray repair cross-complementing protein 1 (XRCC1) loss promotes β-lapachone -induced apoptosis in pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Com | 2021 |
β-lapachone: A Promising Anticancer Agent with a Unique NQO1 Specific Apoptosis in Pancreatic Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Humans; Mice; NAD(P)H Dehydrogenase (Qu | 2022 |
β-lapachone: A Promising Anticancer Agent with a Unique NQO1 Specific Apoptosis in Pancreatic Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Humans; Mice; NAD(P)H Dehydrogenase (Qu | 2022 |
β-lapachone: A Promising Anticancer Agent with a Unique NQO1 Specific Apoptosis in Pancreatic Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Humans; Mice; NAD(P)H Dehydrogenase (Qu | 2022 |
β-lapachone: A Promising Anticancer Agent with a Unique NQO1 Specific Apoptosis in Pancreatic Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Humans; Mice; NAD(P)H Dehydrogenase (Qu | 2022 |
Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Deoxycy | 2017 |
NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone.
Topics: Acrylamides; Cell Death; Cell Line, Tumor; DNA Breaks, Double-Stranded; Drug Synergism; Energy Metab | 2015 |
NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone.
Topics: Acrylamides; Cell Death; Cell Line, Tumor; DNA Breaks, Double-Stranded; Drug Synergism; Energy Metab | 2015 |
NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone.
Topics: Acrylamides; Cell Death; Cell Line, Tumor; DNA Breaks, Double-Stranded; Drug Synergism; Energy Metab | 2015 |
NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone.
Topics: Acrylamides; Cell Death; Cell Line, Tumor; DNA Breaks, Double-Stranded; Drug Synergism; Energy Metab | 2015 |
Combinative effects of β-Lapachone and APO866 on pancreatic cancer cell death through reactive oxygen species production and PARP-1 activation.
Topics: Acrylamides; Cell Death; Cell Line; Cell Line, Tumor; Humans; Immunoblotting; Membrane Potential, Mi | 2015 |
β-Lapachone and Paclitaxel Combination Micelles with Improved Drug Encapsulation and Therapeutic Synergy as Novel Nanotherapeutics for NQO1-Targeted Cancer Therapy.
Topics: Anti-Infective Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma, N | 2015 |
Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone.
Topics: Animals; Autophagy; Catalase; Cell Line, Tumor; Cell Survival; Dicumarol; DNA Breaks, Double-Strande | 2015 |
Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Da | 2016 |
Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; DNA Damage; Drug Evaluation, Preclinic | 2011 |
Efficacy of beta-lapachone in pancreatic cancer treatment: exploiting the novel, therapeutic target NQO1.
Topics: Aged; Animals; Biological Availability; Cyclodextrins; Humans; Male; Mice; Mice, Nude; Naphthoquinon | 2005 |